A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.

Md Abdul Hye KhanLauren KolbMelissa SkibbaMarkus HartmannRené BlöcherEwgenij ProschakJohn D Imig

Published in: Diabetologia (2018)

These findings demonstrate that a novel sHE inhibitor/PPAR-γ agonist molecule targets multiple risk factors of the metabolic syndrome and is a glucose-lowering agent with a strong ability to treat diabetic complications.

Keyphrases

risk factors
metabolic syndrome
insulin resistance
type diabetes
wound healing
adipose tissue
skeletal muscle